Dr. Reddy's Rejuvenation

February 2011
Forbes Asia;Feb2011, Vol. 7 Issue 2, p52
The article discusses latest development occurring at Dr. Reddy's Laboratories after posting a huge loss due to a wrongful acquisition in Europe only 18 months ago. It has been stated that the firm is building a Leadership Academy and is planning to shift its headquarters to Banjara Hills in Hyderabad. It has been stated that run by the second-generation family of founder K. Anji Reddy, the firm has launched a sustained effort to rationalize costs and introduce new products.


Related Articles

  • Dr K Anji Reddy, Founder and Chairman, DRL, passes away.  // Express Pharma;Apr2013, Issue 4, p1 

    An obituary for Dr. K. Anji Reddy, the founder and chairman of pharmaceutical company Dr Reddy's Laboratories Ltd. (DRL) in India, is presented.

  • Dr. Reddy's Founder K. Anji Reddy Dies, 72.  // India -- West;3/29/2013, Vol. 38 Issue 19, pB10 

    An obituary for K. Anji Reddy, founder and chairman of Dr. Reddy's Laboratories Ltd., is presented.

  • LEADERSPEAK.  // Business Today;7/12/2009, Vol. 18 Issue 14, p148 

    The article offers information on the idea about leadership of K. Anji Reddy, chairman of Dr. Reddy's Laboratories Ltd. in India. For Reddy, John F. Kennedy is a political leader that he admires most, while he admires most F .R. D. Tata as a business leader. He relates his leadership lesson in...

  • Generic Drug Blockbusters Timed for Yearly Release. G. P. // Global Finance;Oct2009, Vol. 23 Issue 9, p20 

    The article focuses on the strategic plan of pharmaceutical company Dr. Reddy's Laboratories Ltd. in Hyderabad, India. It states that Dr. Reddy is India's second-biggest drug company and is the major supplier of generic drugs worldwide. It adds that the drug company has planned to increase its...

  • Dr. Reddy's Laboratories Limited SWOT Analysis.  // Dr. Reddys Laboratories, Ltd. SWOT Analysis;Feb2013, p1 

    A business analysis of Dr. Reddy's Laboratories Ltd., an integrated global pharmaceutical company, is provided, focusing on the strengths, weaknesses, opportunities and threats (SWOT) faced by the company. Strengths include its diversified portfolio that caters to emerging markets. Weaknesses...

  • Dr. Reddy's Announces Three Generic Product Launches in the US Market.  // Biomedical Market Newsletter;6/9/2011, p553 

    The article focuses on the generic products which were launched by Dr. Reddy's Laboratories Ltd. in the U.S. market. It says that the launched products were donepezil hydrochloride tablets, venlafaxine hydrochloride extended release capsules, and letrozole tablets. It tells that donepezil...

  • Dr Reddy's Laboratories--good show.  // Chemical Business;Jul98, Vol. 12 Issue 7, p116 

    Reports on the financial performance of the Dr. Reddy's Laboratories company in fiscal year 1997-98. Turnover growth of the formulations business; Formulations sales in India; Sales of the bulk drugs business.

  • Dr Reddy's to expand bulk drug activities.  // Chemical Business;Aug95, Vol. 9 Issue 1, p30 

    Reports that Indian company Dr. Reddy's Lab is contemplating expanding its activities in the fields of bulk drugs as also formulations. Set up of unit by company; Costs; Other expansion by company.

  • Dr. Reddy's Laboratories Inc.  // Pharmaceutical Technology;Dec2010 Supplement, p92 

    The article presents the corporate profile of Dr. Reddy's Laboratories Inc., located in Bridgewater, New Jersey, where it was established in 1984 and has 14,000 active employees.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics